Ricardo Gass , Franciele Plachi , Fernanda O.B. Silva , Talmir Nolasco , Mateus Samuel Tonetto , Leandro S. Goelzer , Paulo T. Muller , Marli M. Knorst , J. Alberto Neder , Danilo C. Berton
{"title":"西地那非对轻度至中度慢性阻塞性肺病患者运动时气体交换、通气和感觉反应的影响:随机交叉试验。","authors":"Ricardo Gass , Franciele Plachi , Fernanda O.B. Silva , Talmir Nolasco , Mateus Samuel Tonetto , Leandro S. Goelzer , Paulo T. Muller , Marli M. Knorst , J. Alberto Neder , Danilo C. Berton","doi":"10.1016/j.resp.2024.104359","DOIUrl":null,"url":null,"abstract":"<div><div>Excess exercise ventilation (high ventilation (V̇<sub>E</sub>)/carbon dioxide output (V̇CO<sub>2</sub>)) contributes significantly to dyspnea and exercise intolerance since the earlier stages of chronic obstructive pulmonary disease (COPD). A selective pulmonary vasodilator (inhaled nitric oxide) has shown to increase exercise tolerance secondary to lower V̇<sub>E</sub>/V̇CO<sub>2</sub> and dyspnea in this patient population. We aimed to assess whether a clinically more practical option - oral sildenafil - would be associated with similar beneficial effects. In a randomized, placebo-controlled study, twenty-four patients with mild-to-moderate COPD completed, on different days, two incremental cardiopulmonary exercise tests (CPET) one hour after sildenafil or placebo. Eleven healthy participants performed a CPET in a non-interventional visit for comparative purposes with patients when receiving placebo. Patients (FEV<sub>1</sub>= 69.4 ± 13.5 % predicted) showed higher ventilatory demands (V̇<sub>E</sub>/V̇CO<sub>2</sub>), worse pulmonary gas exchange, and higher dyspnea during exercise compared to controls (FEV<sub>1</sub>= 98.3 ±11.6 % predicted). Contrary to our expectations, however, sildenafil (50 mg; N= 15) did not change exertional V̇<sub>E</sub>/V̇CO<sub>2</sub>, dead space/tidal volume ratio, operating lung volumes, dyspnea, or exercise tolerance compared to placebo (<em>P</em>>0.05). Due to the lack of significant beneficial effects, nine additional patients were trialed with a higher dose (100 mg). Similarly, active intervention was not associated with positive physiological or sensory effects. In conclusion, acute oral sildenafil (50 or 100 mg) failed to improve gas exchange efficiency or excess exercise ventilation in patients with predominantly moderate COPD. The current study does not endorse a therapeutic role for sildenafil to mitigate exertional dyspnea in this specific patient subpopulation.</div><div>Clinical trial registry: <span><span>https://ensaiosclinicos.gov.br/rg/RBR-4qhkf4</span><svg><path></path></svg></span></div><div>Web of Science Researcher ID: O-7665–2019</div></div>","PeriodicalId":20961,"journal":{"name":"Respiratory Physiology & Neurobiology","volume":"331 ","pages":"Article 104359"},"PeriodicalIF":1.9000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effects of sildenafil on gas exchange, ventilatory, and sensory responses to exercise in subjects with mild-to-moderate COPD: A randomized cross-over trial\",\"authors\":\"Ricardo Gass , Franciele Plachi , Fernanda O.B. Silva , Talmir Nolasco , Mateus Samuel Tonetto , Leandro S. Goelzer , Paulo T. Muller , Marli M. Knorst , J. Alberto Neder , Danilo C. Berton\",\"doi\":\"10.1016/j.resp.2024.104359\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Excess exercise ventilation (high ventilation (V̇<sub>E</sub>)/carbon dioxide output (V̇CO<sub>2</sub>)) contributes significantly to dyspnea and exercise intolerance since the earlier stages of chronic obstructive pulmonary disease (COPD). A selective pulmonary vasodilator (inhaled nitric oxide) has shown to increase exercise tolerance secondary to lower V̇<sub>E</sub>/V̇CO<sub>2</sub> and dyspnea in this patient population. We aimed to assess whether a clinically more practical option - oral sildenafil - would be associated with similar beneficial effects. In a randomized, placebo-controlled study, twenty-four patients with mild-to-moderate COPD completed, on different days, two incremental cardiopulmonary exercise tests (CPET) one hour after sildenafil or placebo. Eleven healthy participants performed a CPET in a non-interventional visit for comparative purposes with patients when receiving placebo. Patients (FEV<sub>1</sub>= 69.4 ± 13.5 % predicted) showed higher ventilatory demands (V̇<sub>E</sub>/V̇CO<sub>2</sub>), worse pulmonary gas exchange, and higher dyspnea during exercise compared to controls (FEV<sub>1</sub>= 98.3 ±11.6 % predicted). Contrary to our expectations, however, sildenafil (50 mg; N= 15) did not change exertional V̇<sub>E</sub>/V̇CO<sub>2</sub>, dead space/tidal volume ratio, operating lung volumes, dyspnea, or exercise tolerance compared to placebo (<em>P</em>>0.05). Due to the lack of significant beneficial effects, nine additional patients were trialed with a higher dose (100 mg). Similarly, active intervention was not associated with positive physiological or sensory effects. In conclusion, acute oral sildenafil (50 or 100 mg) failed to improve gas exchange efficiency or excess exercise ventilation in patients with predominantly moderate COPD. The current study does not endorse a therapeutic role for sildenafil to mitigate exertional dyspnea in this specific patient subpopulation.</div><div>Clinical trial registry: <span><span>https://ensaiosclinicos.gov.br/rg/RBR-4qhkf4</span><svg><path></path></svg></span></div><div>Web of Science Researcher ID: O-7665–2019</div></div>\",\"PeriodicalId\":20961,\"journal\":{\"name\":\"Respiratory Physiology & Neurobiology\",\"volume\":\"331 \",\"pages\":\"Article 104359\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-10-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Respiratory Physiology & Neurobiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1569904824001526\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHYSIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory Physiology & Neurobiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1569904824001526","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHYSIOLOGY","Score":null,"Total":0}
Effects of sildenafil on gas exchange, ventilatory, and sensory responses to exercise in subjects with mild-to-moderate COPD: A randomized cross-over trial
Excess exercise ventilation (high ventilation (V̇E)/carbon dioxide output (V̇CO2)) contributes significantly to dyspnea and exercise intolerance since the earlier stages of chronic obstructive pulmonary disease (COPD). A selective pulmonary vasodilator (inhaled nitric oxide) has shown to increase exercise tolerance secondary to lower V̇E/V̇CO2 and dyspnea in this patient population. We aimed to assess whether a clinically more practical option - oral sildenafil - would be associated with similar beneficial effects. In a randomized, placebo-controlled study, twenty-four patients with mild-to-moderate COPD completed, on different days, two incremental cardiopulmonary exercise tests (CPET) one hour after sildenafil or placebo. Eleven healthy participants performed a CPET in a non-interventional visit for comparative purposes with patients when receiving placebo. Patients (FEV1= 69.4 ± 13.5 % predicted) showed higher ventilatory demands (V̇E/V̇CO2), worse pulmonary gas exchange, and higher dyspnea during exercise compared to controls (FEV1= 98.3 ±11.6 % predicted). Contrary to our expectations, however, sildenafil (50 mg; N= 15) did not change exertional V̇E/V̇CO2, dead space/tidal volume ratio, operating lung volumes, dyspnea, or exercise tolerance compared to placebo (P>0.05). Due to the lack of significant beneficial effects, nine additional patients were trialed with a higher dose (100 mg). Similarly, active intervention was not associated with positive physiological or sensory effects. In conclusion, acute oral sildenafil (50 or 100 mg) failed to improve gas exchange efficiency or excess exercise ventilation in patients with predominantly moderate COPD. The current study does not endorse a therapeutic role for sildenafil to mitigate exertional dyspnea in this specific patient subpopulation.
期刊介绍:
Respiratory Physiology & Neurobiology (RESPNB) publishes original articles and invited reviews concerning physiology and pathophysiology of respiration in its broadest sense.
Although a special focus is on topics in neurobiology, high quality papers in respiratory molecular and cellular biology are also welcome, as are high-quality papers in traditional areas, such as:
-Mechanics of breathing-
Gas exchange and acid-base balance-
Respiration at rest and exercise-
Respiration in unusual conditions, like high or low pressure or changes of temperature, low ambient oxygen-
Embryonic and adult respiration-
Comparative respiratory physiology.
Papers on clinical aspects, original methods, as well as theoretical papers are also considered as long as they foster the understanding of respiratory physiology and pathophysiology.